Send to

Choose Destination
Diagn Microbiol Infect Dis. 2005 Apr;51(4):291-5.

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

Author information

Laboratories International for Microbiology Studies, Schaumburg, IL 60179, USA.


Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa, was 1 microg/mL, including vancomycin-resistant enterococci-, extended-spectrum beta-lactamase-, and methicillin-resistant Staphylococcus aureus-resistant phenotypes.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center